SCHEMBL14033355

SCHEMBL14033355

FC(F)(F)c1ccc(C(Cl)c2ccccc2)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 3/20 0.54
IDO1 P14902 2/20 0.42
TDO2 P48775 2/20 0.42
MAPT P10636 4/20 0.42
ATM Q13315 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
XBP1 P17861 1/20 0.40
HTT P42858 1/20 0.40
S1PR3 Q99500 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 3/20 0.39
ACP3 P15309 2/20 0.39
KCNH2 Q12809 1/20 0.38
TACR1 P25103 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14033737 0.82 PDE2A (0.61) PDE2AIDO1TDO2MAPTATM
SCHEMBL6644323 0.78 PDE2A (0.65) PDE2AMAPTMRGPRX4ALDH1A1KCNH2
SCHEMBL4154570 0.76 ACP3 (0.55) IDO1TDO2ALDH1A1ACP3KCNH2
SCHEMBL4152500 0.75 IDO1 (0.56) IDO1TDO2MAPTSMN1; SMN2LMNA
SCHEMBL7823148 0.73 PDE2A (0.63) PDE2AMAPTMRGPRX4MEN1KMT2A
SCHEMBL14034033 0.73 IDO1 (0.54) IDO1TDO2MAPTMEN1KMT2A
SCHEMBL2629463 0.73 PDE2A (0.73) PDE2AMRGPRX4KCNH2
SCHEMBL10334633 0.72 IDO1 (0.44) PDE2AIDO1TDO2MAPTATM
SCHEMBL8193129 0.72 IDO1 (0.48) PDE2AIDO1TDO2MAPTATM
SCHEMBL9614053 0.72 PDE2A (0.49) PDE2AIDO1TDO2MAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed
EP-1423381-B1 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES SCHERING CORP (US) 2007-01-03 EP disclosed